Fresenius Kabi recalls anti-inflammation drug Ketorolac after finding particles in vials

Fresenius Kabi
Fresenius Kabi was recently knocked by the Chinese government for lots of BeiGene-imported Abraxane. (Fresenius Kabi)

German drugmaker Fresenius Kabi has made major investments in its U.S. manufacturing operations in recent years with some mixed quality results along the way. Now, one of the drugmaker's products faces a recall for more manufacturing woes.

Fresenius Kabi has recalled 13 lots of Ketorolac Tromethamine Injection after carbon, silicon, oxygen and polyamide particulates were found in eight vials of the anti-inflammation drug, the FDA said in an April 20 posting.

The recall covers 30- and 60-milligram doses of the drug distributed between May 5, 2018 and Dec. 16, the FDA said. 

Fresenius has notified its distributor and customers of the recall and advised them "to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product."

RELATED: BeiGene's supply of Bristol Myers Squibb's Abraxane freezes in China amid Fresenius Kabi plant woes

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.